UK Launches Groundbreaking Trial for Prostate Cancer Treatment
A pioneering clinical trial for a novel prostate cancer treatment has commenced in the UK, aiming to mitigate the common side effects associated with conventional surgery. This initiative, supported by the National Institute for Health and Care Research (NIHR), will investigate the effectiveness of Aquablation—a therapy that integrates robotics, artificial intelligence, and real-time imaging—against traditional surgical methods.
Current Surgical Practices and Their Risks
At present, the standard treatment for prostate cancer involves the radical removal of the entire prostate gland, a procedure known as radical prostatectomy. This method is only viable for men whose cancer remains localized to the prostate or has minimally spread to the surrounding area. However, this invasive surgery often results in significant risks, including infection, erectile dysfunction, and urinary complications.
The Promise of Aquablation
Aquablation presents a less invasive alternative aimed at reducing these adverse effects. This innovative treatment employs a high-pressure water jet controlled by robotic assistance, allowing surgeons to create a detailed, real-time map of the prostate using ultrasound technology. This precision enables the targeted removal of cancerous tissue while preserving crucial surrounding nerves and muscles linked to erectile function and bladder control.
Currently, Aquablation is implemented in some medical facilities to address benign prostatic hyperplasia (BPH), but the ongoing trial will broaden its applications to prostate cancer.
Trial Overview and Significance
The international trial, sponsored by US-based Procept BioRobotics, will encompass seven countries, with four sites located in the UK: the Royal Marsden, Guy’s and St Thomas’ NHS Foundation Trust, the Royal Free London NHS Foundation Trust, and Norfolk and Norwich University Hospitals NHS Foundation Trust. A total of 280 patients globally, all in the early stages of localized prostate cancer and already committed to surgical intervention, are set to be enrolled in the trial.
Dr. Philip Charlesworth, a consultant urological surgeon at the Royal Marsden, highlighted the importance of addressing the side effects of cancer treatments. He remarked on the trial’s potential to preserve post-surgery quality of life for men by leveraging new technologies for better outcomes.
Increasing Prostate Cancer Rates
Statistics from Prostate Cancer UK reveal that approximately one in eight men will receive a prostate cancer diagnosis in their lifetime. Recent figures indicate that 58,218 men were diagnosed in England last year, reflecting a nearly 9% increase compared to the previous year.
Controversial Screening Guidelines
The call for routine prostate cancer screening remains contentious. Last month, advisers declared that extending screening to the majority of men might do more harm than good. Instead, they recommended biennial screenings for men possessing BRCA1 and BRCA2 genetic mutations, who are at an elevated risk for developing prostate cancer, beginning at age 45.
While there is a growing advocacy for broader screening, notably from public figures such as Olympian Sir Chris Hoy and Sky News presenter Dermot Murnaghan, who are both battling advanced prostate cancer, the decision to limit screening has raised eyebrows. Former Prime Minister Lord Cameron has also voiced support for expanded screening measures following his own prostate cancer treatment.
Background
The introduction of Aquablation therapy marks a significant shift in the approach to prostate cancer treatment and addresses the increasing concern regarding the side effects of existing surgical methods. The advancements in technology, coupled with rising cancer diagnosis rates, highlight the urgent need for innovative treatment options that prioritise patient quality of life.
Source: Original Article
